Description: Calocurb® CLINICAL is a practitioner-exclusive supplement that supports appetite control by working with the body’s natural hormonal signals. It features Amarasate®, a clinically studied extract of New Zealand bitter hops, delivered in a delayed-release capsule designed to reach the small intestine where it activates bitter taste receptors. This triggers the release of key satiety hormones including GLP-1, CCK and PYY, which work together to significantly reduce hunger, cravings, and caloric intake. Fast-acting and plant-based, Calocurb® CLINICAL offers a targeted, science-driven approach to supporting healthy weight management. Clinical Applications Reduces Appetite and Food Cravings Supports Long-Term Weight Management Stimulates Natural GLP-1, CCK and PYY Release Complements Lifestyle and Pharmaceutical Weight Loss Strategies Enhances Adherence to Intermittent Fasting and Time-Restricted Eating Benefits In 2019, the first clinical study on Amarasate® was conducted in a randomized, double-blind trial investigating its appetite suppressive effects during a 24-hour, water-only fast. Participants given Amarasate® or placebo at hours 16 and 20 were evaluated for hunger and satiety with a standard visual analog scale (VAS) every 30 minutes after capsule administration. Amarasate® participants reported an 80% reduction in hunger elevation scores compared to the placebo group. In a comparable water-fast study conducted in women, Amarasate® supplementation led to a 100% suppression of hunger elevation and a 120% reduction in food cravings relative to placebo. A more expansive study of adult men sought to correlate the subjective reduction in hunger from the first study with anorexigenic biomarkers, specifically GLP-1, CCK and PYY. The study also sought to investigate which was more efficacious, intragastric or intraduodenal delivery of Amarasate®. In the randomized, double-blind study, the subjects were given either placebo, intraduodenal Amarasate® (delayed-release capsule), or intragastric Amarasate® (immediate-release capsule) one hour before an ad libitum meal and subsequent snack. Both Amarasate® delivery methods had significant elevations in GLP-1, CCK and PYY; however, the intragastric capsule also had significantly more adverse events than the intraduodenal capsule likely due to the high amount of TAS2R bitter receptors in the stomach. Intraduodenal delivery of Amarasate® resulted in 600% elevation from baseline of GLP-1 and CCK, and 50% elevation of PYY. Directions for Use: Contains: 60 x 250 mg capsulesPatients should continue on a dose of Calocurb® CLINICAL 250 mg twice daily, using the Maintenance Pack.Take one 250 mg capsule, twice daily, one hour before a meal.Always take on an empty stomach with a minimum of 8 ounces of water.DOES NOT CONTAINSugar, starch, yeast, wheat, gluten, soy, milk, eggs, shellfish, fish, peanuts, tree nuts. No artificial colors, flavors or preservatives. *Claims are from the manufacturer and not Victress Health or wholesaler*
